OptiNose (OPTN) to Release Quarterly Earnings on Thursday

OptiNose (NASDAQ:OPTN) is anticipated to release its earnings data before the market opens on Thursday, March 20th. Analysts expect OptiNose to post earnings of ($0.67) per share and revenue of $21.02 million for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

OptiNose Trading Up 9.7 %

OptiNose stock opened at $5.88 on Tuesday. OptiNose has a 1-year low of $4.82 and a 1-year high of $31.50. The firm has a market capitalization of $59.15 million, a price-to-earnings ratio of -1.40 and a beta of -0.30. The firm’s fifty day moving average price is $5.80 and its two-hundred day moving average price is $8.30.

Wall Street Analysts Forecast Growth

OPTN has been the topic of a number of recent analyst reports. Lake Street Capital dropped their price target on shares of OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. HC Wainwright raised their price target on shares of OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, January 3rd.

Insiders Place Their Bets

In other news, CEO Ramy A. Mahmoud sold 6,376 shares of OptiNose stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the completion of the transaction, the chief executive officer now owns 126,931 shares in the company, valued at $671,464.99. This trade represents a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.30% of the company’s stock.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.